FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/14/2025
Back to search
Official data from USPTO
VISCOFAN FIBERCOLL-FLEX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
VISCOFAN FIBERCOLL-FLEX
ST13
US500000079353016Class
1, 2, 5
Filing
79353016
Registration
7497685
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
03/15/2025
Trademark type
Word
Nice classes
1, 2, 5
Filing date
07/28/2022
Registration date
09/10/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/10/2024
Last transaction
03/15/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
88
Owner location
ES
Examiner
TWOHIG,SHANNON MARIE
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
VISCOFAN, S.A.
Representatives
Douglas A. Miro Amster, Rothstein & Ebenstein LLP
Technical classification
Nice Classes
Class 1Class 2Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological materials or preparations for 3D printersbioinksbioprinting kits comprised of collagenbiological printed tissues other than for medical or veterinary purposes; hydrogels for cell culture not for medical or veterinary purposes; hydrogels for cell growth not for medical or veterinary purposes; cell culture media other than for medical or veterinary use; nutritional agents for processing living cells other than for medical usecell culture media within a reservoir for growth factors; culture media for microbiology for laboratory use; reagents for scientific and medical research; synthetic peptides not for pharmaceutical purposespeptide substrates used in analyzing and detecting certain toxins for laboratory or research use; synthetic peptide derivatives not for pharmaceutical purposespeptide substrates used in analyzing and detecting certain toxins for laboratory or research use; cells other than for medicalveterinary or pharmaceutical use; cells or tissues in hydrogels other than for medicalveterinary or pharmaceutical use; biologically compatible polymersspecifically hydrogels used to produce polymer networks used in the manufacture of engineered living tissues for medicalscientific and non-scientific purposestissue implantsorganoidstissue models; cell culture media for use in the biotechnological industry for laboratory use; cell culture media for use in non-medical research laboratories; biological preparations for use in cell cultureother than for medical and veterinary purposes; engineered living tissues and tissue arrayshuman and animal organsconnective tissueepithelial tissuemuscular tissue and nervous tissuetissue arraysfor use in scientific and medical research; biologically compatible materialsspecificallyhydrogels used to create polymeric networks used in the manufacture of living tissues for laboratory use; proteins in the form of raw materials for scientific and medical research
Class 2
Inks of biological origin for printers; inks of biological origin for 3D printers
Class 5
Hydrogels for medicalveterinary and pharmaceutical purposes for cellular biology applications; hydrogels for cell growthcell growth and transplantationassays based on cellscancer cell researchregenerative medicinestem cell growth and drug delivery for medical use; hydrogels for cell culture for medicalveterinary and pharmaceutical purposes; hydrogels for cell growth for medicalveterinary and pharmaceutical purposes; cell culture media for medical use; nutritional agents for processing living cellscell culture media growth factors contained within a reservoir; synthetic peptides for the treatment of degenerated hard and soft tissues; synthetic peptide derivativesfor the treatment of degenerated hard and soft tissues; cells for medicalveterinary and pharmaceutical use; cells or tissues in hydrogels for medicalveterinary or pharmaceutical use; pharmaceutical preparations for use in 3D bio-printing of tissues and organs; pharmaceutical preparations with other materials and ingredients for use in 3D bio-printing of tissues and organs; regenerative tissue being pharmaceutical preparations for hard and soft tissue regeneration; cells for medical use; allogeneic human tissue; living cells for medical use; implants containing living tissue; implantable living tissue materials for use in guided tissue regeneration; skin grafts; surgical implants formed by living tissue; surgical implants of living tissues derived from stem cells; transdermal patches for the creation of skin for prostheses and skin grafts; living tissue for transplants; engineered biological tissues and organshuman and animal cardiovascularpulmonarydigestivehepatobiliaryurologicalrenalendocrineepithelialmuscularnervous tissues and organsfor medical purposes; biological molecules being implants comprising living tissue to assist in tissue engineeringhard and soft tissue regeneration; hemostatic gel matrix preparations for wound treatment; natural biomaterials for the growth of bonesblood and tissues for medical purposes; pharmaceutical products for the regeneration of tissuesfor the repair of tissuesfor the treatment of tissueswhether human or animal3D implants for hard and soft tissue regeneration combining bioinks and biological materials; pharmaceutical preparations for the treatment of diseases of bonescartilagesblood vesselsnerve cell degenerationtendon and ligament degenerationretinal degenerationkidney degeneration; soft tissue degenerationsfor diseases with abnormal cell growthformulated bioinks for hard and soft tissue regeneration combining bioinks and biological materials with a pharmaceutical effect; natural biomaterial for bone filling; natural biomaterial for cartilage filling; biological tissue cultures for medical use; biological tissue cultures for medical purposes; biological tissue grafts; bone and skin biological tissues impregnated with oxygen lines for tissue constructs applicable for increasing the cell survival in tissue intended for subsequent implants; gene therapy productsgenetically modified tissues for the transplant thereof; implantable stents composed primarily of living tissue to maintain the structure of the tissue; natural biomaterial for bone and tissue growth for medical purposes
Publications
History of USPTO decisions and trademark events.
35 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/20/2025
FIMP
FINAL DISPOSITION PROCESSED
02/19/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/10/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/10/2024
GPNX
NOTIFICATION PROCESSED BY IB
07/01/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/25/2024
PUBO
PUBLISHED FOR OPPOSITION
06/25/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/11/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/17/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/09/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/09/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/20/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/20/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/01/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/29/2023
GNFR
FINAL REFUSAL E-MAILED
11/29/2023
CNFR
FINAL REFUSAL WRITTEN
11/29/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/20/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/20/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/20/2023
RFNT
REFUSAL PROCESSED BY IB
05/17/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/22/2023
RFRR
REFUSAL PROCESSED BY MPU
04/22/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/01/2023
CNRT
NON-FINAL ACTION WRITTEN
02/28/2023
DOCK
ASSIGNED TO EXAMINER
02/23/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/25/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/21/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/20/2022
Continuous trademark protection
Get notified about every new filing that threatens VISCOFAN FIBERCOLL-FLEX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.